Journal article

Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: A review

GD Burrows, KP Maguire, TR Norman

JOURNAL OF CLINICAL PSYCHIATRY | PHYSICIANS POSTGRADUATE PRESS | Published : 1998

Abstract

Reboxetine is a unique selective norepinephrine reuptake inhibitor (NRI) with proven antidepressant efficacy in pharmacologic and biochemical tests predictive of antidepressant properties. Comprehensive clinical trials, including 8 placebo-controlled and/or active treatment-controlled studies, plus 4 open studies, have assessed the short-term and long-term efficacy and tolerability of reboxetine in patients with major depressive disorders and dysthymia. Results from a total of 690 patients who entered 5 open or placebo-controlled studies are summarized in this paper. Four hundred forty-nine patients with a diagnosis of either major depressive disorder or dysthymia were treated with reboxetin..

View full abstract

University of Melbourne Researchers